Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/MAP3K20_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/MAP3K20_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/MAP3K20_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/MAP3K20_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/MAP3K20_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/MAP3K20_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00351131 | Endometrium | EEC | embryonic appendage morphogenesis | 23/2168 | 116/18723 | 6.73e-03 | 3.93e-02 | 23 |
GO:00073467 | Endometrium | EEC | regulation of mitotic cell cycle | 70/2168 | 457/18723 | 8.76e-03 | 4.74e-02 | 70 |
GO:00072543 | Liver | NAFLD | JNK cascade | 38/1882 | 167/18723 | 1.12e-06 | 5.52e-05 | 38 |
GO:00714795 | Liver | NAFLD | cellular response to ionizing radiation | 21/1882 | 72/18723 | 4.93e-06 | 1.83e-04 | 21 |
GO:00514036 | Liver | NAFLD | stress-activated MAPK cascade | 47/1882 | 239/18723 | 5.26e-06 | 1.93e-04 | 47 |
GO:00310986 | Liver | NAFLD | stress-activated protein kinase signaling cascade | 48/1882 | 247/18723 | 5.89e-06 | 2.07e-04 | 48 |
GO:00712145 | Liver | NAFLD | cellular response to abiotic stimulus | 56/1882 | 331/18723 | 7.01e-05 | 1.47e-03 | 56 |
GO:01040045 | Liver | NAFLD | cellular response to environmental stimulus | 56/1882 | 331/18723 | 7.01e-05 | 1.47e-03 | 56 |
GO:00714783 | Liver | NAFLD | cellular response to radiation | 33/1882 | 186/18723 | 8.76e-04 | 1.07e-02 | 33 |
GO:00427703 | Liver | NAFLD | signal transduction in response to DNA damage | 30/1882 | 172/18723 | 1.93e-03 | 1.94e-02 | 30 |
GO:20010206 | Liver | NAFLD | regulation of response to DNA damage stimulus | 36/1882 | 219/18723 | 2.14e-03 | 2.08e-02 | 36 |
GO:00714803 | Liver | NAFLD | cellular response to gamma radiation | 9/1882 | 31/18723 | 2.67e-03 | 2.44e-02 | 9 |
GO:20010224 | Liver | NAFLD | positive regulation of response to DNA damage stimulus | 20/1882 | 105/18723 | 3.71e-03 | 3.16e-02 | 20 |
GO:1901987 | Liver | NAFLD | regulation of cell cycle phase transition | 56/1882 | 390/18723 | 4.01e-03 | 3.36e-02 | 56 |
GO:0000077 | Liver | NAFLD | DNA damage checkpoint | 21/1882 | 115/18723 | 5.00e-03 | 3.92e-02 | 21 |
GO:0000075 | Liver | NAFLD | cell cycle checkpoint | 28/1882 | 169/18723 | 5.61e-03 | 4.28e-02 | 28 |
GO:00102123 | Liver | NAFLD | response to ionizing radiation | 25/1882 | 148/18723 | 6.67e-03 | 4.74e-02 | 25 |
GO:00073463 | Liver | Cirrhotic | regulation of mitotic cell cycle | 154/4634 | 457/18723 | 8.73e-06 | 1.29e-04 | 154 |
GO:007121411 | Liver | Cirrhotic | cellular response to abiotic stimulus | 115/4634 | 331/18723 | 2.62e-05 | 3.38e-04 | 115 |
GO:010400411 | Liver | Cirrhotic | cellular response to environmental stimulus | 115/4634 | 331/18723 | 2.62e-05 | 3.38e-04 | 115 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MAP3K20 | SNV | Missense_Mutation | rs565333842 | c.5N>T | p.Ser2Leu | p.S2L | Q9NYL2 | protein_coding | tolerated_low_confidence(0.45) | benign(0.003) | TCGA-C8-A275-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MAP3K20 | SNV | Missense_Mutation | | c.1061A>G | p.Lys354Arg | p.K354R | Q9NYL2 | protein_coding | tolerated(0.23) | possibly_damaging(0.596) | TCGA-D8-A27I-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adrimycin+cyclophosphamide | SD |
MAP3K20 | SNV | Missense_Mutation | | c.2218N>T | p.Pro740Ser | p.P740S | Q9NYL2 | protein_coding | deleterious_low_confidence(0.02) | benign(0.015) | TCGA-E2-A15A-06 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD |
MAP3K20 | insertion | Frame_Shift_Ins | novel | c.2347_2348insAGCCTCAGGATCTCTCCTGTGGACACGTGAA | p.Ala783GlufsTer15 | p.A783Efs*15 | Q9NYL2 | protein_coding | | | TCGA-B6-A0RE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MAP3K20 | SNV | Missense_Mutation | | c.1456N>A | p.Glu486Lys | p.E486K | Q9NYL2 | protein_coding | deleterious(0.01) | possibly_damaging(0.836) | TCGA-C5-A1BK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
MAP3K20 | SNV | Missense_Mutation | novel | c.1024N>A | p.Asp342Asn | p.D342N | Q9NYL2 | protein_coding | deleterious(0.02) | benign(0.21) | TCGA-VS-A8EK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD |
MAP3K20 | SNV | Missense_Mutation | novel | c.1288N>A | p.Glu430Lys | p.E430K | Q9NYL2 | protein_coding | tolerated(0.57) | benign(0.007) | TCGA-VS-A958-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
MAP3K20 | SNV | Missense_Mutation | novel | c.407C>T | p.Ser136Leu | p.S136L | Q9NYL2 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-ZJ-AAXJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
MAP3K20 | deletion | Frame_Shift_Del | | c.659delN | p.Asn222ThrfsTer4 | p.N222Tfs*4 | Q9NYL2 | protein_coding | | | TCGA-VS-A94Z-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
MAP3K20 | SNV | Missense_Mutation | | c.1129C>T | p.Arg377Trp | p.R377W | Q9NYL2 | protein_coding | deleterious(0) | probably_damaging(0.966) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
51776 | MAP3K20 | KINASE, DRUGGABLE GENOME, SERINE THREONINE KINASE, ENZYME | | CYC-116 | CYC-116 | |
51776 | MAP3K20 | KINASE, DRUGGABLE GENOME, SERINE THREONINE KINASE, ENZYME | | GNF-PF-3023 | CHEMBL535331 | |
51776 | MAP3K20 | KINASE, DRUGGABLE GENOME, SERINE THREONINE KINASE, ENZYME | | LAS38096 | CHEMBL375293 | |
51776 | MAP3K20 | KINASE, DRUGGABLE GENOME, SERINE THREONINE KINASE, ENZYME | | CENISERTIB | CENISERTIB | |
51776 | MAP3K20 | KINASE, DRUGGABLE GENOME, SERINE THREONINE KINASE, ENZYME | | SP-600125 | SP-600125 | |
51776 | MAP3K20 | KINASE, DRUGGABLE GENOME, SERINE THREONINE KINASE, ENZYME | | ILORASERTIB | ILORASERTIB | |
51776 | MAP3K20 | KINASE, DRUGGABLE GENOME, SERINE THREONINE KINASE, ENZYME | inhibitor | 384403681 | | |
51776 | MAP3K20 | KINASE, DRUGGABLE GENOME, SERINE THREONINE KINASE, ENZYME | | DOVITINIB | DOVITINIB | |
51776 | MAP3K20 | KINASE, DRUGGABLE GENOME, SERINE THREONINE KINASE, ENZYME | | GW441756X | GW441756X | |
51776 | MAP3K20 | KINASE, DRUGGABLE GENOME, SERINE THREONINE KINASE, ENZYME | | SNS-314 | SNS-314 | |